Butanetap and GLP1 agonist Trulicity have synergistic effect in pre-clinical testing in mice with Alzheimer’s . . .

[redhawk1]

. . . not sure is anything meaningful . . . just thought such synergy between the two medications was interesting.

[redhawk1]

Here is link to story . . .

globenewswire.com/news-rele...

[park_bear in reply to redhawk1]

Do not know how good this model is but the results seem pretty good

Buntanetap + GLP-1

[WinnieThePoo in reply to park_bear]

When did this research take place?

Where did it take place?

Where has it been published ? (link please)

Observations :

Annovis Bio have been releasing a string of "happy, but not science" news stories with no backup data since their sole product failed to meet primary endpoints in both phase 3 AD and PD trials

The 2018 mouse data referred to was not repeated in humans in those recent trials

Liraglutide's positive effects on AD related measures in mice has been known since at least 2011

"Liraglutide has been tested in preclinical AD models. In the APP/PS1 transgenic mouse, liraglutide reduced amyloid deposition, glial activation, and synapse loss, increased neurogenesis, and improved memory (McClean et al., 2011)" alzforum.org/therapeutics/l...

The potential of liraglutide in AD was first referenced by Annovis at AAIC 2024. Liraglutide just completed a phase 2a trial for AD, at Imperial College (UK) showing promising results. People, not mice

Buntanetap has just completed a phase 3 trial in humans not mice which failed